333 related articles for article (PubMed ID: 17163154)
1. EWS-FLI1 in Ewing's sarcoma: real targets and collateral damage.
Ban J; Siligan C; Kreppel M; Aryee D; Kovar H
Adv Exp Med Biol; 2006; 587():41-52. PubMed ID: 17163154
[TBL] [Abstract][Full Text] [Related]
2. A molecular function map of Ewing's sarcoma.
Kauer M; Ban J; Kofler R; Walker B; Davis S; Meltzer P; Kovar H
PLoS One; 2009; 4(4):e5415. PubMed ID: 19404404
[TBL] [Abstract][Full Text] [Related]
3. Identification of an inhibitor of the EWS-FLI1 oncogenic transcription factor by high-throughput screening.
Grohar PJ; Woldemichael GM; Griffin LB; Mendoza A; Chen QR; Yeung C; Currier DG; Davis S; Khanna C; Khan J; McMahon JB; Helman LJ
J Natl Cancer Inst; 2011 Jun; 103(12):962-78. PubMed ID: 21653923
[TBL] [Abstract][Full Text] [Related]
4. The evaluation of CD99 immunoreactivity and EWS/FLI1 translocation by fluorescence in situ hybridization in central PNETs and Ewing's sarcoma family of tumors.
Vural C; Uluoğlu O; Akyürek N; Oğuz A; Karadeniz C
Pathol Oncol Res; 2011 Sep; 17(3):619-25. PubMed ID: 21267687
[TBL] [Abstract][Full Text] [Related]
5. Ewing's sarcoma oncoprotein EWS-FLI1: the perfect target without a therapeutic agent.
Uren A; Toretsky JA
Future Oncol; 2005 Aug; 1(4):521-8. PubMed ID: 16556028
[TBL] [Abstract][Full Text] [Related]
6. A zebrafish transgenic model of Ewing's sarcoma reveals conserved mediators of EWS-FLI1 tumorigenesis.
Leacock SW; Basse AN; Chandler GL; Kirk AM; Rakheja D; Amatruda JF
Dis Model Mech; 2012 Jan; 5(1):95-106. PubMed ID: 21979944
[TBL] [Abstract][Full Text] [Related]
7. Caveolin-1 (CAV1) is a target of EWS/FLI-1 and a key determinant of the oncogenic phenotype and tumorigenicity of Ewing's sarcoma cells.
Tirado OM; Mateo-Lozano S; Villar J; Dettin LE; Llort A; Gallego S; Ban J; Kovar H; Notario V
Cancer Res; 2006 Oct; 66(20):9937-47. PubMed ID: 17047056
[TBL] [Abstract][Full Text] [Related]
8. FOXO1 is a direct target of EWS-Fli1 oncogenic fusion protein in Ewing's sarcoma cells.
Yang L; Hu HM; Zielinska-Kwiatkowska A; Chansky HA
Biochem Biophys Res Commun; 2010 Nov; 402(1):129-34. PubMed ID: 20933505
[TBL] [Abstract][Full Text] [Related]
9. Hsa-mir-145 is the top EWS-FLI1-repressed microRNA involved in a positive feedback loop in Ewing's sarcoma.
Ban J; Jug G; Mestdagh P; Schwentner R; Kauer M; Aryee DN; Schaefer KL; Nakatani F; Scotlandi K; Reiter M; Strunk D; Speleman F; Vandesompele J; Kovar H
Oncogene; 2011 May; 30(18):2173-80. PubMed ID: 21217773
[TBL] [Abstract][Full Text] [Related]
10. Promiscuous partnerships in Ewing's sarcoma.
Sankar S; Lessnick SL
Cancer Genet; 2011 Jul; 204(7):351-65. PubMed ID: 21872822
[TBL] [Abstract][Full Text] [Related]
11. EWS-FLI1 target genes recovered from Ewing's sarcoma chromatin.
Siligan C; Ban J; Bachmaier R; Spahn L; Kreppel M; Schaefer KL; Poremba C; Aryee DN; Kovar H
Oncogene; 2005 Apr; 24(15):2512-24. PubMed ID: 15735734
[TBL] [Abstract][Full Text] [Related]
12. Hypoxia modulates EWS-FLI1 transcriptional signature and enhances the malignant properties of Ewing's sarcoma cells in vitro.
Aryee DN; Niedan S; Kauer M; Schwentner R; Bennani-Baiti IM; Ban J; Muehlbacher K; Kreppel M; Walker RL; Meltzer P; Poremba C; Kofler R; Kovar H
Cancer Res; 2010 May; 70(10):4015-23. PubMed ID: 20442286
[TBL] [Abstract][Full Text] [Related]
13. PI3K/AKT signaling modulates transcriptional expression of EWS/FLI1 through specificity protein 1.
Giorgi C; Boro A; Rechfeld F; Lopez-Garcia LA; Gierisch ME; Schäfer BW; Niggli FK
Oncotarget; 2015 Oct; 6(30):28895-910. PubMed ID: 26336820
[TBL] [Abstract][Full Text] [Related]
14. EWS-FLI-1 expression triggers a Ewing's sarcoma initiation program in primary human mesenchymal stem cells.
Riggi N; Suvà ML; Suvà D; Cironi L; Provero P; Tercier S; Joseph JM; Stehle JC; Baumer K; Kindler V; Stamenkovic I
Cancer Res; 2008 Apr; 68(7):2176-85. PubMed ID: 18381423
[TBL] [Abstract][Full Text] [Related]
15. [Ewing's tumours, genetic and cellular aspects].
Delattre O
Pathol Biol (Paris); 2008 Jul; 56(5):257-9. PubMed ID: 18485618
[TBL] [Abstract][Full Text] [Related]
16. Junction region of EWS-FLI1 fusion protein has a dominant negative effect in Ewing's sarcoma in vitro.
Jully B; Vijayalakshmi R; Gopal G; Sabitha K; Rajkumar T
BMC Cancer; 2012 Nov; 12():513. PubMed ID: 23145994
[TBL] [Abstract][Full Text] [Related]
17. NR0B1 is required for the oncogenic phenotype mediated by EWS/FLI in Ewing's sarcoma.
Kinsey M; Smith R; Lessnick SL
Mol Cancer Res; 2006 Nov; 4(11):851-9. PubMed ID: 17114343
[TBL] [Abstract][Full Text] [Related]
18. Small-molecule screen identifies modulators of EWS/FLI1 target gene expression and cell survival in Ewing's sarcoma.
Boro A; Prêtre K; Rechfeld F; Thalhammer V; Oesch S; Wachtel M; Schäfer BW; Niggli FK
Int J Cancer; 2012 Nov; 131(9):2153-64. PubMed ID: 22323082
[TBL] [Abstract][Full Text] [Related]
19. High-throughput RNAi screen in Ewing sarcoma cells identifies leucine rich repeats and WD repeat domain containing 1 (LRWD1) as a regulator of EWS-FLI1 driven cell viability.
He T; Surdez D; Rantala JK; Haapa-Paananen S; Ban J; Kauer M; Tomazou E; Fey V; Alonso J; Kovar H; Delattre O; Iljin K
Gene; 2017 Jan; 596():137-146. PubMed ID: 27760381
[TBL] [Abstract][Full Text] [Related]
20. Preclinical Justification of pbi-shRNA EWS/FLI1 Lipoplex (LPX) Treatment for Ewing's Sarcoma.
Rao DD; Jay C; Wang Z; Luo X; Kumar P; Eysenbach H; Ghisoli M; Senzer N; Nemunaitis J
Mol Ther; 2016 Aug; 24(8):1412-22. PubMed ID: 27166877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
